ANEMIA HEMOLÍTICA INDUCIDA POR MEDICAMENTOS: UNA REVISIÓN SISTEMÁTICA
DOI:
https://doi.org/10.47820/recima21.v3i12.2463Palabras clave:
Anemia hemolítica, Hemólisis, MedicamentosResumen
La anemia hemolítica inducida por fármacos (AHIM) es una complicación rara, resultante de la interacción de ciertas sustancias con la membrana del eritrocito, que puede ser fatal si no se aclara rápidamente. La anemia puede ocurrir en respuesta al uso de cualquier terapia farmacológica y muchas veces es infradiagnosticado. Así, el presente estudio tiene como objetivo realizar una revisión sistemática de la literatura sobre anemia hemolítica inducida por fármacos en PubMed, Biblioteca Virtual en Salud (BVS) y Capes Periodicals publicada en los últimos cinco años. Durante el estudio se seleccionaron 19 artículos científicos en la presente revisión, de los cuales 18 fueron reportes de casos y 1 fue un estudio retrospectivo. Se observó que en sólo un estudio, el desenlace clínico resultante de la AHIM fue la muerte del paciente. En total, la investigación reveló 19 principios activos relacionados con la hemólisis inducida por fármacos.
Descargas
Citas
Al-Ansari RY, KHURAIM AA, Abdalla L, Hamid H, Zakary NY. Remsima (a Tumor Necrosis Factor (TNF)-α Inhibitor) induced hemolysis in a patient with Crohn's disease-Case report. Ann. Med. Surg. 2021;69(1):102768.
Mioti AGX, De Castro GFP. Alterações hematológicas induzidas por anti-inflamatórios não-esteroidais. Rev. Transformar. 2017;10(1):170-183
Mohammad S, Clowse MEB, Eudy AM, Criscione-Schreiber LG. Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6 PDH‐Deficient Patients. Arthritis Care Res; 2018;70(3):481-485.
Wu Y, Wu, Y, Yang Y, Chen B, Li J, Guo G, Xiong F. Case Report: First Case of Cefotaxime-Sulbactam-Induced Acute Intravascular Hemolysis in a Newborn With ABO Blood Type Incompatibility by the Mechanism of Non-Immunologic Protein Adsorption. Frontiers in immunology. 2021;12:698541.
Belfield KD, Tichy EM. Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency. Am J Health Syst Pharm. 2018;75(3):97-104,
Afra F, Mehri M, Namazi S. Bosentan-induced immune hemolytic anemia in 17 years old man. A case report. DARU Journal of Pharmaceutical Sciences. 2021; 29(1):211-215.
Agbuduwe C, Rugless M, Asba N, Proven M, Sivakumaran M. Severe drug-induced hemolysis in a patient with compound heterozygosity for Hb Peterborough (HBB: c. 334G> T) and Hb Lepore-Boston-Washington (NG_000007. 3: g. 63632_71046del). Hemoglobin, 2019;43(1): 56-59.
Gniadek TJ, Arndt PA, Leger RM, Zydowicz D, Cheng EY, Zantek ND. Drug‐induced immune hemolytic anemia associated with anti‐vancomycin complicated by a paraben antibody. Transfusion. 2018;58(1):181-188.
Quintanilla-Bordás C, Castro-Izaguirre E, Carcelén-Gadea M, Marín M. The first reported case of drug‐induced hemolytic anemia caused by dimethyl fumarate in a patient with multiple sclerosis. Transfusion. 2019;59(5):1648-1650.
Esteves A, Silva FT, Carvalho J, Carvoeiro A, Falgueiras P. Diclofenac-Induced Immune Hemolytic Anemia: A Case Report and Review of Literature. Cureus. 2021;13(1):e12903.
Gomez JC, Saleem T, Snyder S, Joseph M, Kanderi T. Drug-induced immune hemolytic anemia due to amoxicillin-clavulanate: a case report and review. Cureus. 2020;12(6):e8666.
Nguyen, TN, Maenulein E, Fihman V, Vinatier I, Moh Klaren J. Serologic characteristics of oxaliplatin antibodies in 15 patients with drug‐induced immune hemolytic anemia. Transfusion. 2021;61(5):1609-1616.
Wu S, Jing L, Feng Y, Chen L. Marked reduction in haemoglobin levels secondary to ceftizoxime-induced immune haemolytic anaemia in diabetic patients. J Clin Pharm Ther. 2020;45(4):812-814.
Dara RC, Sharma R, Bhardwaj H. Severe drug-induced immune hemolysis due to ceftriaxone. Asian J. Transfus. Sci. 2020;14(2)187-191.
Hamid NC, Malek KA, Nasir NM, Nasir NM. Pneumocystis jirovecii Pneumonia with a Normal Early Chest Radiography and Complicated with Drug-Induced Immune Hemolytic Anemia: A Case Report. The American Journal of Case Reports. 2022;23:e936278-1.
HIill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol. 2017;177(2):208-220.
Havey TC, Cserti-Gazdewich C, Sholzberg M, Keystone JS, Gold WL. Case report: recurrent disseminated intravascular coagulation caused by intermittent dosing of rifampin. Am J Trop Med. 2012;86(2):264-267.
Sanwal C, Kaldas A, Surani S, Bailey M. Rifampin-Induced Acute Intravascular Hemolysis Leading to Heme Pigment-Related Kidney Injury. Cureus. 2020;12(7):e9120.
Stevens-Cohen P, Zaghi F, Zhu L. A Rare Case of Hydrochlorothiazide-Induced Hemolytic Anemia. Cureus. 2021;13(8):e17453.
Johnson ST, Fueger JT, Gottschal JL. One center's experience: the serology and drugs associated with drug‐induced immune hemolytic anemia—a new paradigm. Transfusion. 2007;47(4):697-702, 2007.
BAE, Ju Young et al. Anemia hemolítica Coombs-negativa em um homem com COVID-19. Relatos de Casos Clínicos , v. 9, n. 7, pág. e04503, 2021.
Garratty G, Arndt PA. Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007. Immunohematology. 2014;30(2);66-79.
Gong JH, Liu GJ, Zhou F, Sun ZQ. Dabigatran-induced chronic progressive immune hemolytic anemia: A case report. J. Stroke Cerebrovasc. Dis. 2020;29(8):1-2.
Ishii H, Sato T, Ishibashi M, Yokoyama H, Saito T, Tasaki T, et al. A case of immune complex type hemolytic anemia by initial micafungin administration. Int J Infect Dis. 2022;0(0):755–757.
Wu Y, Wu Y, Ji Y, Liu Y, Wu D, Liang J, et al. Case Report: Oral Cimetidine Administration Causes Drug-Induced Immune Hemolytic Anemia by Eliciting the Production of Cimetidine-Dependent Antibodies and Drug-Independent Non-specific Antibodies. Front Med. 2021;8:1–9
Lois TAE, López-Polín A, Norman FF, Monge-Maillo B, López-Vélez, R, Perez-Molina JA. Delayed haemolysis secondary to treatment of severe malaria with intravenous artesunate: Report on the experience of a referral centre for tropical infections in Spain. Travel medicine and infectious disease. 2017;15:52–56.
Fanello C, Onyamboko M, Lee SJ, Woodrow C, Setaphan S, Chotivanick K et al. Post-treatment haemolysis in African children with hyperparasitaemic falciparum malaria; a randomized comparison of artesunate and quinine. BMC Infect. Dis. 2017;17(1):575-583.
Camprubí D, Pereira A, Rodriguez-Valero N, Almuedo A, Varo R, Calsas-Pascual C et al. Positive direct antiglobulin test in post-artesunate delayed haemolysis: more than a coincidence? Malar. J. 2019;18(1)128-135.
Savargaonkar D, Das MK, Verma A, Miltra JK, Yadav CP, Srivastava B. Delayed haemolysis after treatment with intravenous artesunate in patients with severe malaria in India. Malar J. 2020;19(1):39-45.
Lo YH, MOK K. L. High dose vitamin C induced methemoglobinemia and hemolytic anemia in glucose-6-phosphate dehydrogenase deficiency. Am J Emerg Med. 2020;38(11):2488.e3-2488.e5.
Maillart E, Leemans S, Van Noten H, Vandergraesen T, Mahadeb B, Salaouatchi MT et al. A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine. Infect Dis. 2020;52(9):659–61.
Descargas
Publicado
Cómo citar
Número
Sección
Categorías
Licencia
Derechos de autor 2022 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
Clique para ver detalhes 
